IN8bio (INAB) Expected to Post Earnings on Thursday

IN8bio (NASDAQ:INAB) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.3437) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

IN8bio (NASDAQ:INAB) last issued its earnings results on Thursday, May 7th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.33. On average, analysts expect IN8bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

IN8bio Price Performance

NASDAQ:INAB opened at $1.07 on Thursday. The firm has a market capitalization of $10.54 million, a price-to-earnings ratio of -0.41 and a beta of 0.22. The company’s 50-day moving average is $1.44 and its two-hundred day moving average is $1.64. IN8bio has a 1-year low of $1.05 and a 1-year high of $2.73.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on INAB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of IN8bio in a research report on Thursday, June 4th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, IN8bio presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Alyeska Investment Group L.P. increased its position in shares of IN8bio by 1,060.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock valued at $2,231,000 after acquiring an additional 875,000 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of IN8bio by 381.6% in the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after acquiring an additional 724,637 shares during the last quarter. Two Sigma Investments LP purchased a new position in shares of IN8bio during the 3rd quarter worth approximately $107,000. Citadel Advisors LLC purchased a new position in shares of IN8bio during the 3rd quarter worth approximately $54,000. Finally, Captrust Financial Advisors acquired a new stake in IN8bio in the 4th quarter valued at approximately $43,000. Hedge funds and other institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.